Angion Biomedica Corp. Advances BB3 into Pivotal Phase 3 Clinical Trial in Renal Transplant Patients with Delayed Graft Function (PDF)
Angion Biomedica Corp. To Commence Phase 2 Clinical Trial of BB3 in Acute Kidney Injury (PDF)
Since 1998 Angion has been developing treatments for major organ diseases.
One in 10 American adults, more than 20 million, has some level of chronic kidney disease.
Angion is testing new treatments to reduce or prevent kidney injury.